1. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application
- Author
-
Rongrong Zhou, Han Wang, Zhiyuan Liu, Haiqin Peng, Hexin Duan, Jiahui Li, Lei Yang, Xuan Gao, and Gang Xiao
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Immunology ,Ipilimumab ,Pembrolizumab ,03 medical and health sciences ,0302 clinical medicine ,Atezolizumab ,Carcinoma, Non-Small-Cell Lung ,PD-L1 ,Internal medicine ,Animals ,Humans ,Immunology and Allergy ,Medicine ,Lung cancer ,Immune Checkpoint Inhibitors ,neoplasms ,biology ,Brain Neoplasms ,business.industry ,Tumor-infiltrating lymphocytes ,medicine.disease ,Immune checkpoint ,respiratory tract diseases ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,Nivolumab ,business ,medicine.drug - Abstract
Brain metastases (BM) is common in non-small-cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors (ICIs) have gradually become a routine treatment for NSCLC BM patients. Currently, three PD-1 inhibitors (pembrolizumab, nivolumab and cemiplimab), one PD-L1 inhibitor (atezolizumab) and one CTLA-4 inhibitor (ipilimumab) have been approved for the first-line treatment of metastatic NSCLC. It is still controversial whether PD-L1, tumor infiltrating lymphocytes, and tumor mutation burden can be used as predictive biomarkers for immune checkpoint inhibitors in NSCLC patients with BM. In addition, clinical data on NSCLC BM were inadequate. Here, we review the theoretical basis and clinical data for the application of ICIs in the therapy of NSCLC BM.
- Published
- 2021
- Full Text
- View/download PDF